VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB

Part I:

This part of the study is designed to demonstrate the dose equivalence between off-label
aerosolized epoprostenol and VentaProst using a patient's hemodynamic parameters.

Part II:

This part of the study is designed to establish a dose response relationship of VentaProst to
hemodynamic effect by dose escalation in patients who have had cardiac surgery with CPB.

Inclusion Criteria:

1. Women and Men 18 to 75 years of age

2. Provide written informed consent

3. Willing and able to comply with all aspects of the protocol

4. For patients in Part I:

1. Undergo cardiac surgery on CPB

2. Clinically require treatment with and receive aerosolized epoprostenol

3. Demonstrate a clinically meaningful hemodynamic response to aerosolized
epoprostenol

5. For patients in Part II:

1. Undergo cardiac surgery with CPB

2. Have perioperative pulmonary hypertension

3. Clinically require treatment with inhaled epoprostenol

Exclusion Criteria:

1. Current smoker (i.e., within the last 30 days)

2. Emergency operative status

3. Upper and/or lower respiratory tract infection within four weeks of screening

4. Contraindication to transesophageal echocardiogram (TEE) including esophageal disease
or unstable cervical spine

5. Renal or severe hepatic impairment

6. Thromboembolic disease treated with anticoagulant therapy

7. Bleeding disorders

8. Significant restrictive or obstructive lung disease

9. History of concurrent malignancy or recurrence of malignancy within two years prior to
Screening

10. History of a diagnosis of drug or alcohol dependency or abuse within approximately the
last three years

11. Recent history of stroke or transient ischemic attack

12. Significantly abnormal laboratory tests at Screening

13. Pregnant or breastfeeding

14. Treatment with an investigational drug, biologic, or device within 30 days

15. Other severe, acute, or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with trial participation or
investigational product administration or may interfere with the interpretation of
trial results and, in the judgment of the Investigator or Sponsor, would make the
patient inappropriate for entry into this trial

16. Any condition where aerosolized epoprostenol is contraindicated

17. Known allergy or sensitivity to epoprostenol, any of its ingredients, or the diluent